The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

Show other versions (1)

The aberrant activation of the phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) pathway is common in pancreatic ductal adenocarcinomas (PDAC). The application of inhibitors against PI3K and AKT has been considered as a therapeutic option. We investigated PDAC cell lines exposed to increasing...

Full description

Bibliographic Details
Main Authors: Al-Ali, R. (Author), Ameziane, N. (Author), Bauer, P. (Author), Escobar, H.M (Author), Junghanss, C. (Author), Kong, W. (Author), Krake, S. (Author), Lerch, M.M (Author), Ma, Y. (Author), Parveen, A. (Author), Radefeldt, M. (Author), Sekora, A. (Author), Sender, S. (Author), Weiss, F.U (Author), Zechner, D. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
KRAS
pancreatic ductal adenocarcinoma
PI3K/AKT pathway
TP53
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items